<DOC>
	<DOCNO>NCT03049267</DOCNO>
	<brief_summary>Study design : A double-blind randomise placebo-controlled trial Intervention : Randomized placebo control treatment 20 HS patient fifteen patient randomize apremilast five patient placebo . The total duration treatment period per subject 16 week . Primary objective : To evaluate expression profile inflammatory cytokine HS lesional skin week four ( t=4 ) week sixteen ( t=16 ) : - patient receive apremilast compare placebo ; - within group relative baseline ( t=0 ) . Secondary objective : - To prospectively evaluate clinical efficacy apremilast . - To assess effect apremilast patient report outcomes measure . - To assess short-term safety tolerability apremilast patient hidradenitis suppurativa .</brief_summary>
	<brief_title>Short-term Safety , Efficacy Mode Action Apremilast Moderate Suppurative Hidradenitis</brief_title>
	<detailed_description>Rationale : Hidradenitis suppurativa ( HS ) chronic , inflammatory , recurrent , debilitate skin disease . It characterize painful , deep-seated , inflamed boil inverse area body , commonly axillae , inguinal anogenital region . Systemic therapy immunosuppressive agent ( systemic corticosteroid , dapsone , cyclosporin ) investigate past decade show limited efficacy . The use selective immunosuppressant apremilast yet evaluate HS . The investigator hypothesize beneficial effect apremilast HS patient , similar efficacy apremilast psoriasis patient . Namely , show immune dysregulation pathogenesis HS show many similarity psoriasis . Moreover , TNF-α blocker adalimumab register HS approval treatment patient psoriasis .</detailed_description>
	<mesh_term>Hidradenitis</mesh_term>
	<mesh_term>Hidradenitis Suppurativa</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Key inclusion criterion : Adult ( ≥ 18 year age ) male female patient moderate HS accord PGA 3 5point HSPhysician Global Assessment ( HSPGA ) ; HS 6 month duration ; lesion least two anatomical location . Key exclusion criterion : Contraindication apremilast ; previous use apremilast ; current and/or recurrent clinically significant skin condition treatment area HS ; Presence uncontrolled major disease ; Pregnant lactate woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>acne inversa</keyword>
</DOC>